All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Shilpa Medicare's NorUDCA tablets secure first-ever CDSCO approval for non-alcoholic fatty liver disease therapy
Small molecule, metabolic, liver disease, NAFLD, first-in-class therapy - Read more

THE GOOD
Business Development & Partnerships

Eli Lilly, Superluminal partner on GPCR-targeting small molecules for cardiometabolic diseases and obesity in $1.3B deal
Small molecule, obesity, cardiometabolic disease, AI/ML, licensing deal, milestone payments - Read more

Basilea, Venatorx partner on Phase III-ready oral antibiotic combo for cUTI; deal worth up to $325M plus royalties
Licensing deal, infectious disease, small molecule, milestone payments, royalties - Read more

Avista Therapeutics partners with Forge Biologics for AAV gene therapy development and cGMP manufacturing of XLRS treatment candidate
Manufacturing agreement, gene therapy, rare disease, ophthalmology, cGMP manufacturing - Read more

Eli Lilly partners with Goodpath to expand self-pay access to Zepbound via LillyDirect platform
Digital health, commercialization, telehealth partnership, weight management, prescription access, US - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

TYK Medicines' Asandeutertinib shows positive brain response in Ph2 trial for EGFR-mutant non-small cell lung cancer
Small molecule, cancer, kinase inhibitor, non-small cell lung cancer, EGFR mutation, brain metastases - Read more

THE GOOD
Fundraises

bioAffinity Technologies raises $1.2M private placement, developing noninvasive early-stage cancer detection tests
Cancer, diagnostics, early detection, biotechnology, platform technology - Read more

Aquestive Therapeutics secures $75M strategic funding from RTW to launch anaphylaxis treatment film
Pharmaceutical, drug delivery technology, sublingual film, anaphylaxis, allergic reaction treatment - Read more

THE GOOD
Market Reports

AstraZeneca and Merck & Co. lead oncology marketing with Enhertu and Keytruda promotions to healthcare professionals
Monoclonal antibody, oncology, promotional strategy, competitive landscape, market influence - Read more

THE GOOD
Mergers & Acquisitions

Norgine acquires Theravia, expanding into rare disease treatments for high-unmet medical needs
Rare disease, strategic, major transaction, acquisition - Read more

THE GOOD
Politics & Policy

Trump orders HHS to stockpile 26 essential drug ingredients, prioritizing US manufacturers amid onshoring push
Pharmaceutical supply chain, manufacturing, active pharmaceutical ingredients, regulatory, strategic, national security - Read more

President Trump's pharma tariffs likely to be delayed by weeks despite threats of 250% levies, Reuters reports
Pharmaceutical manufacturing, trade policy, financial, operational, regulatory - Read more

THE BAD
Approvals & Labels

China revokes Green Valley's conditional approval for GV-971 targeting Alzheimer's disease amid efficacy concerns
Small molecule, neurological, Alzheimer's disease, drug approval, seaweed-derived, China market - Read more

THE BAD
Clinical Trials

Prelude Therapeutics pauses Ph1 SMARCA2 degrader PRT3789 after underwhelming results in non-small cell lung cancer
Small molecule, cancer, protein degrader, non-small cell lung cancer, SMARCA2 target, SMARCA4 mutation - Read more

THE BAD
Investments

Sana Biotechnology cancels Washington manufacturing plant, shifts to CDMOs after $44.6 million impairment charge
Cell therapy, diabetes, operational, cost reduction, strategic - Read more

THE BAD
Layoffs

TriLink BioTechnologies cuts 90 jobs as parent Maravai launches $50M cost-saving restructuring plan
mRNA manufacturing, CDMO, layoffs, cost reduction, operational restructuring - Read more

Evotec cuts 600 jobs in reorganization targeting €40M annual savings
Contract research, manufacturing, operational, cost reduction, strategic - Read more

Vedanta Biosciences cuts 20% of staff after VE202 fails ulcerative colitis trial; shifts focus to C. diff treatment
Microbiome therapy, inflammatory bowel disease, clinical setback, staff reduction, strategic refocus - Read more

THE BAD
Politics & Policy

HHS revives childhood vaccine safety task force under NIH Director Bhattacharya amid RFK Jr.'s anti-vaccine agenda
Vaccine safety, infectious disease, regulatory, policy change, political - Read more

THE BAD
Strategic Plans

Eli Lilly plans European drug price hikes, responding to Trump's pricing pressure
Diabetes medicine, endocrinology, pricing strategy, regulatory, international markets, political - Read more

THE UGLY
Clinical Trials

Schrödinger halts Ph1 CDC7 blocker SGR-2921 after two deaths in acute myeloid leukemia study
Small molecule, cancer, CDC7 inhibitor, acute myeloid leukemia, myelodysplastic syndromes, clinical trial safety - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here